Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-6,899
Closed -$2.84M 298
2024
Q2
$2.84M Sell
6,899
-1,442
-17% -$571K 0.46% 118
2024
Q1
$3.37M Sell
8,341
-4,087
-33% -$1.44M 0.53% 107
2023
Q4
$3.81M Buy
12,428
+6,392
+106% +$1.73M 0.68% 47
2023
Q3
$1.46M Buy
+6,036
New +$1.54M 0.28% 167
2020
Q2
Sell
-23,378
Closed -$1.72M 293
2020
Q1
$1.72M Buy
+23,378
New +$2.03M 0.53% 74
2019
Q4
Sell
-21,149
Closed -$1.78M 290
2019
Q3
$1.78M Buy
+21,149
New +$1.6M 0.47% 78
2019
Q1
Sell
-28,911
Closed -$1.53M 293
2018
Q4
$1.53M Sell
28,911
-20,052
-41% -$1.1M 0.42% 103
2018
Q3
$2.93M Buy
+48,963
New +$2.68M 0.44% 114

Other funds holding MEDP

EAM Investors's MEDP Position: Q3 2024 in Review

EAM Investors sold out of Medpace (MEDP) in Q3 2024, closing a stake of 6,899 shares — an estimated $2.84M sold.

EAM Investors first reported a position in MEDP in Q3 2018 and held it in 8 quarters. The position peaked at $3.81M in Q4 2023. 583 funds tracked by Wall St. Rank hold MEDP as of Q3 2024.

  • EAM Investors reported no remaining Medpace position as of Q3 2024 after selling out during the quarter.
  • EAM Investors sold 6,899 Medpace shares in Q3 2024, an estimated $2.84M.
  • EAM Investors first reported a position in Medpace in Q3 2018 and held it in 8 quarters.
  • EAM Investors's Medpace position peaked at $3.81M in Q4 2023.
  • 583 funds tracked by Wall St. Rank held Medpace as of Q3 2024.

Based on EAM Investors's 13F filing for Q3 2024, filed 13 Nov 2024.